Navigation Links
Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
Date:7/22/2008

arb Counting) (P=.70); respective values for A1C <6.5 percent were 44.3 percent and 49.5 percent (P=.28). The Simplified Algorithm group had 53 episodes of severe hypoglycemia in 19 patients, and the Carb Counting group had 37 episodes in 19 patients, leading to estimates of 0.89 and 0.67 event/patient-year for the two groups (P=0.58). SMBG < 50 mg/dL with symptoms was slightly but statistically significantly more common in the Carb Counting group than in the Simplified Algorithm group (8.0 vs. 4.9 events/patient-year, P=0.02).

"A combination of basal and bolus insulin may be needed to achieve optimal glucose control in type 2 diabetes patients," explained study author Richard M. Bergenstal, MD, executive director, International Diabetes Center, Park Nicollet Health Services, Minneapolis, MN. "The simplified algorithm investigated in this study allowed patients to start with a fixed dose of Apidra(R) and then effectively adjust to target based on premeal glucose patterns, or to use carbohydrate counting, which involves a mathematical formula that helps patients match the size of their mealtime insulin dose with the amount of carbohydrates they eat. Having two effective options for managing mealtime insulin doses may increase patients' and clinicians' willingness to initiate basal-bolus therapy."

Throughout the study, SMBG levels were recorded before meals and at bedtime each day, as well as a 7-point blood glucose profile at weeks 2, 6, 12, 18, and 24 (endpoint). Blood glucose values at each visit declined in both arms, and the within-group change from baseline was statistically significant over all daily time points and study visits. By the study's conclusion, both arms significantly improved fasting plasma glucose (FPG) levels as well, with averages of 112.0 mg/dl in the Simplified Algorithm group and 101.8 mg/dl in the Carb Counting group (P<0.0001 for both groups).

"Type 2 diabetes is a progressive disease that requires treatment adjustments
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
4. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
5. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
6. Newly Approved HIV Drug Shows Great Promise
7. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
8. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
9. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 AFFiRiS ... New York results of AFF008, a Phase I ... is the first therapy against the protein alpha-synuclein, a promising ... Michael J. Fox Foundation for Parkinson,s Research (MJFF) supported the ... the press conference on the impact a disease-modifying therapy would ...
(Date:7/31/2014)... and LONDON , July 31, 2014 /PRNewswire/ ... services provider for the medical industries, announced today the incorporation of ... United Kingdom has one of the largest ... 8.9 billion in 2012 and it is projected to increase by ... USD 234 billion in 2012, equal to 9.5% of GDP. Despite ...
(Date:7/31/2014)... , July 31, 2014 Vermillion, Inc. (NASDAQ: ... women,s health, will hold a conference call on Thursday, August ... for the second quarter ended June 30, 2014. Financial results ... call. Vermillion,s Chairman, President and CEO James ... and answer period. Date: Thursday, August 14, 2014 ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4genae Opens Offices in London 2Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2
... 02, 2007 /PRNewswire-FirstCall/ - YM,BioSciences Inc. ... develops,and commercializes differentiated products for patients ... randomized,placebo-controlled Phase IIb trial of AeroLEF(TM) ... following orthopedic surgery.,AeroLEF(TM) met the primary ...
... 2, 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) ... clinical trial,of Fampridine-SR in people with multiple ... meeting. Andrew Goodman, M.D.,Director of the Multiple ... top-line results on walking ability, leg,strength, spasticity ...
Cached Medicine Technology:YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 2YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets,Primary Endpoint in Patients with Post-Surgical Pain 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:7/31/2014)... Andrie, Inc. V. Dept. of Treasury, Mich. ... Court has made the determination that a purchaser of tangible ... taxpayer was unable to prove during an audit that ... the Court of Appeals decision on whether a purchaser bears ... for purchases from Michigan sellers. The Court states “in order ...
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... recently released their innovative compression elbow sleeve , ... other elbow pain, in two new bright colors for ... neon pink and blue. Made of innovative proprietary Zensah® ... moisture wicking and odor-preventing fabric. It features a no-slip ...
(Date:7/31/2014)... 2014 Parker Waichman, LLP, a national ... comments that whistleblowers are a critical component of the ... that may cause harm to consumers and may defraud ... Appreciation Day. , According to a 2013 report issued ... declared "National Whistleblower Appreciation Day" on July 30, 2013; ...
(Date:7/31/2014)... 31, 2014 CarePoint Health is ... Masood Rizvi, has joined our network, CarePoint Health ... the community. Hundreds of highly skilled and experienced ... network of top doctors and practices in Hudson ... latest acquisition represents CarePoint Health’s commitment to provide ...
(Date:7/31/2014)... CT (PRWEB) July 31, 2014 You’re having ... So why have you suddenly developed chills and fever, headache, ... If you suspect a flu-like illness, it could actually be ... , Your risk of developing Lyme is greater than you ... 30,000 new cases occurred in the U.S. annually. But the ...
Breaking Medicine News(10 mins):Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 2Health News:Taxpayer Failing To Prove Sales Tax Was Paid At Time Of Purchase Results In Use Tax Due 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 2Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 4Health News:Dr. Rizvi Joins CarePoint Health Medical Group 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 2Health News:Feel Like You Have A Summertime 'Flu'? It Could Be Lyme Disease 3
... equal for both procedures , , FRIDAY, May 16 ... for colon cancer produce similar outcomes, according to researchers ... 3,300 patients. , "For a long time, many ... in colorectal cancer patients and cause metastases in the ...
... ,Click It or Ticket ... Local high schoolers display art and videos promoting seat belt use, CLEVELAND, May ... mobilization, When: Monday, May 19, 2008 ... 11:30 AM), Where: The Cleveland House of Blues ...
... of CSL Behring, maker of Zemaira(R), Alpha-1 Proteinase Inhibitor (Human) ... ... PRUSSIA, Pa., May 17 Melissa Biggs, a fashion,designer and actress who ... of CSL Behring, and is,urging Americans to get tested for alpha-1 antitrypsin ...
... & Back; Merger Sets Up Healthy ... Back Retail Chain, LORTON, Va., May 16 ... and workplace back wellness created an,ergonomic revolution, has acquired ... Healthy Back,s 18 stores and ecommerce division,claimed 2007 revenues ...
... There,s more to a healthy mouth than,flashing a ... America,s oral care,habits - and what it means ... report from Oral Health America & Philips Sonicare ... video, audio, text, graphics and,photos for free and ...
... report side effects, but critics want agency to act, ... -- Direct-to-consumer drug ads on television should include a ... adverse side effects, U.S. health experts suggested Friday. , ... U.S. Food and Drug Administration. Such phone numbers are ...
Cached Medicine News:Health News:Outcomes Similar for Laparoscopic, Open Colon Cancer Surgeries 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:The Back Wars Come to a Close 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
Gills Colibri forceps, very fine pointed tips....
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Girard angled tying forceps made of titanium has angled 45 shafts with 4 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 102 mm....
McPherson curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, flat handle, width 6 mm, overall length 85 mm....
Medicine Products: